Thrombosis and haemostasis research : Stimulating, hard work and funBLOMBÄCK, Margareta.Thrombosis and haemostasis. 2007, Vol 98, Num 1, pp 8-15, issn 0340-6245, 8 p.Article

Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutationANTOVIC, Jovan P; BLOMBÄCK, Margareta.Thrombosis research. 2002, Vol 106, Num 1, pp 59-62, issn 0049-3848Article

Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materialsSHU HE; HONGLIE CAO; ANTOVIC, Aleksandra et al.Blood coagulation & fibrinolysis. 2005, Vol 16, Num 1, pp 61-67, issn 0957-5235, 7 p.Article

A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research workSHU HE; ANTOVIC, Aleksandra; BLOMBÄCK, Margareta et al.Thrombosis research. 2001, Vol 103, Num 5, pp 355-361, issn 0049-3848Article

Platelet activity, coagulation, and fibrinolysis during exercise in healthy males : Effects of thrombin inhibition by argatroban and enoxaparinNAILIN LI; SHU HE; BLOMBÄCK, Margareta et al.Arteriosclerosis, thrombosis, and vascular biology. 2007, Vol 27, Num 2, pp 407-413, issn 1079-5642, 7 p.Article

Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red lightSUONTAKA, Anna-Maija; BLOMBÄCK, Margareta; CHAPMAN, John et al.Transfusion (Philadelphia, PA). 2003, Vol 43, Num 5, pp 568-575, issn 0041-1132, 8 p.Article

On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressinEDLUND, Mans; BLOMBÄCK, Margareta; SHU HE et al.Blood coagulation & fibrinolysis. 2003, Vol 14, Num 6, pp 593-598, issn 0957-5235, 6 p.Article

Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations?SKEPPHOLM, Mika; WALLEN, N. Hakan; BLOMBÄCK, Margareta et al.Clinical chemistry and laboratory medicine. 2008, Vol 46, Num 8, pp 1175-1179, issn 1434-6621, 5 p.Article

Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal womenHALL, Gerd; BLOMBÄCK, Margareta; LANDGREN, Britt-Marie et al.Fertility and sterility. 2002, Vol 78, Num 6, pp 1172-1177, issn 0015-0282, 6 p.Article

Bedside monitoring of coagulation activation after challenging healthy volunteers with intravenous endotoxinUNGERSTEDT, Johanna S; SOOP, Anne; SOLLEVI, Alf et al.Thrombosis research. 2003, Vol 111, Num 6, pp 329-334, issn 0049-3848, 6 p.Article

Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?SKEPPHOLM, Mika; KALLNER, Anders; MALMQVIST, Karin et al.Thrombosis research. 2011, Vol 128, Num 5, pp 483-489, issn 0049-3848, 7 p.Article

Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregationYOO, Gina; BLOMBÄCK, Margareta; GUSTAFSSON, Karin Schenck et al.British journal of haematology. 2003, Vol 121, Num 1, pp 123-129, issn 0007-1048, 7 p.Article

The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysisSHU HE; BLOMBÄCK, Margareta; BARK, Niklas et al.Thrombosis and haemostasis. 2010, Vol 103, Num 5, pp 1076-1084, issn 0340-6245, 9 p.Article

A fibrinogen concentrate Haemocomplettan^® (Riastap^®) or a Factor XIII concentrate Fibrogammin^® combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitorSHU HE; JOHNSSON, Hans; ZABCZYK, Michal et al.British journal of haematology. 2013, Vol 160, Num 6, pp 806-816, issn 0007-1048, 11 p.Article

ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitusSKEPPHOLM, Mika; KALLNER, Anders; KALANI, Majid et al.Blood coagulation & fibrinolysis. 2009, Vol 20, Num 8, pp 619-626, issn 0957-5235, 8 p.Article

Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentratesSHU HE; JOHNSSON, Hans; ZABCZYK, Michal et al.Thrombosis and haemostasis. 2014, Vol 111, Num 3, pp 417-428, issn 0340-6245, 12 p.Article

In vivo roles of factor XIIRENNE, Thomas; SCHMAIER, Alvin H; NICKEL, Katrin F et al.Blood. 2012, Vol 120, Num 22, pp 4296-4303, issn 0006-4971, 8 p.Article

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrateBLOMBÄCK, Margareta; SHU HE; BARK, Niklas et al.British journal of haematology. 2011, Vol 152, Num 6, pp 758-765, issn 0007-1048, 8 p.Article

Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasmaANTOVIC, Aleksandra; BLOMBÄCK, Margareta; STEN-LINDER, Margareta et al.Blood coagulation & fibrinolysis. 2005, Vol 16, Num 8, pp 585-596, issn 0957-5235, 12 p.Article

Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complicationsANTOVIC, Jovan P; YNGEN, Marianne; ÖSTENSON, Claes-Göran et al.Blood coagulation & fibrinolysis. 2003, Vol 14, Num 6, pp 551-556, issn 0957-5235, 6 p.Article

Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcersKALANI, Majid; SILVEIRA, Angela; BLOMBÄCK, Margareta et al.Thrombosis research. 2007, Vol 120, Num 5, pp 653-661, issn 0049-3848, 9 p.Article

Are results of fibrinogen measurements transferable?KALLNER, Anders; EGBERG, Nils; YU, Anna et al.Clinical chemistry and laboratory medicine. 2003, Vol 41, Num 6, pp 804-808, issn 1434-6621, 5 p.Article

Effect of dalteparin on healing of Chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: A prospective, randomized, double-blind, placebo-controlled studyKAIANI, Majid; APELQVIST, Jan; BLOMBÄCK, Margareta et al.Diabetes care. 2003, Vol 26, Num 9, pp 2575-2580, issn 0149-5992, 6 p.Article

In Vitro Effects of Argatroban, Lepirudin, Bivalirudin, and Danaparoid on Fibrin Gel PermeabilitySHU HE; WALLEN, Hakan; JOHNSSON, Hans et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, pp 91-96, issn 0094-6176, 6 p., SUP1Article

Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic strokeROOTH, Elisabeth; WALLEN, Hakan; ANTOVIC, Alexandra et al.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 4, pp 365-370, issn 0957-5235, 6 p.Article